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Abstract Tumor angiogenesis has been identified to play 
a critical role in tumor growth and tumor progression, 
and is regulated by a balance of angiogenic and antian-
giogenic cytokines. This has been documented for solid 
tumors, and there is emerging evidence suggesting that 
tumor progression of hematological malignancies also 
depends on the induction of new blood vessel formation. 
Data on angiogenesis in the bone marrow of BCR-ABL1-
negative myeloproliferative neoplasm patients suggest 
an increase of the microvessel density and vascular 
endothelial growth factor (VEGF) expression, and there 
is a relation to the JAK2-V617F status. The most impor-
tant proangiogenic agent is VEGF, activating VEGF recep-
tors 1 and 2. Inhibition of VEGF signaling by monoclonal 
antibodies or small molecules (kinase inhibitors) has 
already been successfully established for the treatment 
of different cancer entities, and multiple new drugs are 
being tested in clinical trials. Most patients with essential 
thrombocythemia (ET) or primary myelofibrosis (PMF) 
that was not associated with a JAK2 or MPL alteration 
carried a somatic mutation in calreticulin (CALR). Thus, 
CALR mutations should be included in the next clas-
sification system for ET/PMF. This review summarizes 
recent advances in the basic understanding of the role 
of angiogenesis in myeloproliferative neoplasms and the 
translation of such basic findings into clinical studies.
Keywords Angiogenesis  · Microvessel density  · Myelo-
proliferative neoplasms · Primary myelofibrosis · Vascu-
lar endothelial growth factor
Introduction
Angiogenesis, new blood vessel formation, is funda-
mental to tumor growth and spread [1]. Tumors require 
nutrients and oxygen to grow, and new blood vessels, 
formed by angiogenesis, provide these substrates [2]. The 
key mediator of angiogenesis is the vascular endothelial 
growth factor (VEGF). Its expression is regulated by a 
plethora of intrinsic and extrinsic factors, with hypoxia 
and hypoglycemia being the major stimuli [3]. Little 
is known about the exact trigger mechanisms of VEGF 
expression in hematolymphoid tumors, but mechanisms 
analogous to those observed in solid tumors are antici-
pated [4, 5]. Tight control of angiogenesis is maintained 
by a balance of endogenous antiangiogenic and proan-
giogenic factors. VEGF has a key, rate-limiting role in 
promoting tumor angiogenesis and exerts its effects by 
binding to one of three tyrosine kinase receptors: VEGF 
receptor-1 (VEGFR-1; fms-like tyrosine kinase-1, Flt-1), 
VEGFR-2 (human kinase domain region, KDR/murine 
fetal liver kinase-1, Flk-1), and VEGFR-3 (Flt-4) [6, 7].
The identification of an acquired somatic mutation 
in the JAK2 gene, resulting in a valine to phenylalanine 
substitution at position 617 (JAK2-V617F), has provided 
new insights into the pathogenesis of BCR-ABL1-nega-
tive myeloproliferative neoplasms (MPN), being pres-
ent in most patients with polycythemia vera (PV) and in 
approximately 50 % of patients with essential thrombo-
cythemia (ET) and primary myelofibrosis (PMF) [8, 9]. 
Although the molecular diagnostic gap in JAK2V617F-
negative PV was adequately addressed by the discovery 
of other JAK2 mutations, the same had not been realized 
for the 35–40 % of patients with ET or PMF who do not 
express JAK2 mutations. In December 2013, two groups 
reported the occurrence of novel calreticulin (CALR) 
mutations in JAK2/MPL-unmutated PMF or ET [10, 11]. 
Both groups found mutual exclusivity between CALR, 
JAK2, and MPL mutations. In the study by Klampfl et al., 
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CALR mutations were not seen in 382 cases of PV but 
were detected in 25 % of patients with ET (n = 311) and 
35 % of those with PMF (n = 203).
Pathophysiology of angiogenesis in MPN
We and the others showed that angiogenesis and expres-
sion of VEGF and its receptors in the bone marrow of 
patients with BCR-ABL1-negative MPN is increased, espe-
cially in PMF [12–17]. We found significantly increased 
microvessel density (MVD), particularly that assessed 
by CD105, and VEGF expression in MPN compared with 
controls (PMF > PV > MDS/MPN > ET) [12]. We observed 
stronger association between CD105-MVD and VEGF 
expression, fibrosis, and JAK2-V617F mutant allele bur-
den, compared with CD34-MVD. CD105-MVD probably 
better reflects angiogenic activity in MPN than CD34-
MVD. CD105/endoglin is a cell transmembrane glyco-
protein and a key component of transforming growth 
factor-β receptor complex [18]. It is mainly expressed 
by angiogenic endothelial cells and has been correlated 
with tumor MVD [19]. CD105 is preferentially expressed 
by newly formed vessels [20, 21], and thus, CD105-based 
MVD quantification better reveals ongoing proangio-
genic activity. MVD was strongly increased in MPN with 
high JAK2-V617F mutant allele burden. Considering cor-
relations between the JAK2-V617F status and angiogene-
sis in MPN, we showed that MVD, particularly if assessed 
by CD105, in PV and PMF patients correlate with a high 
JAK2-V617F mutant allele burden (≥ 55 % mutant alleles), 
but not with the diagnostic level for JAK2 mutations of 
3 %. These observations implicate that higher activity of 
JAK2-related pathways, as observed in cases with higher 
JAK2-V617F mutant allele burdens, may influence angio-
genesis in MPN. This assumption is further supported 
by our observation that VEGF+ cellular amounts did not 
concurrently rise with increasing JAK2-V617F mutant 
allele burden regardless of rising MVD [12].
Whether this observed increased neovasculariza-
tion in neoplastic bone marrow is instrumental for the 
neoplastic process or rather an “innocent bystander” 
resulting from growth factors and cytokines being out of 
balance can only be determined by carefully designed 
experiments and clinical studies where inhibition of the 
angiogenic process does or does not inhibit the growth of 
the neoplasm.
Antiangiogenic therapy in myeloproliferative 
neoplasms
Antiangiogenic therapies are mostly based on inhibiting 
the binding of VEGF to VEGFR by neutralizing antibod-
ies to the ligand or to the receptor, soluble receptors, or 
small molecule inhibitors or are directed against the tyro-
sine kinase activity of the VEGF receptors (Table 1) [22]. A 
growing list of antiangiogenics is now available, either in 
various stages of clinical development or as components 
of standard clinical regimens. The major classes of anti-
angiogenic therapy include (1) receptor tyrosine kinase 
inhibitors (TKI), targeting VEGFR signaling as well as 
receptors of other (proangiogenic) factors, (2) direct anti-
VEGF acting molecules (anti-VEGF antibodies, VEGF-
antisense nucleotides), and (3) immunomodulatory 
drugs (IMiDs) with antiangiogenic properties [22].
Table 1 Selection of clinical trials and approved antiangiogenic therapies in hematological malignancies
Drug Target Study entities Approved for
Receptor tyrosine kinase inhibitors
PTK787/ZK 222584 (Vatalanib®) VEGFR1-3, PDGFRβ, c-Kit AML, PMF, MDS, CML, DLBCL, MM
SU5416 (Semaxinib) VEGFR1-2, c-kit, Flt3 AML, MDS, MM, MPN
Sorafenib (Nexavar®) VEGFR2-3, B-Raf, Faf-1, PDGFRβ AML, ALL, MDS, CML, CLL, NHL, MM Advanced renal cell carcinoma, HCC
Sunitinib (Sutent®) VEGFR1-3, PDGFRα + β, c-kit, Flt3 AML, MDS, CLL, myeloma, NHL Advanced renal cell carcinoma, GIST
PKC-412 (Midostaurin) VEGFR2, PKC, PDGFR, Flt3, c-Kit AML
Cediranib (Recentin®) VEGFR1-3, PDGFRβ, c-Kit AML, MDS, CLL
Proteasome inhibitors
Bortezomib (Velcade®) 26S proteasome, NF-κB AML, ALL, MDS, CML, NHL, MCL MM, MCL
Anti-VEGF strategies
Bevacizumab (Avastin®) VEGF-A AML, MDS, CLL, CML, NHL, MM Metastatic colorectal cancer, NSCLC, 
breast cancer
Immunomodulatory drugs
Thalidomide bFGF, VEGF, IL-6 AML, MDS, MPN, CLL, NHL, MM MM
Lenalidomide (Revlimid®) bFGF, VEGF, IL-6 AML, MDS, CLL, NHL MM, 5q-MDS
AML acute myeloid leukemia, bFGF basic fibroblast growth factor, DLBCL diffuse large B-cell lymphoma, CLL chronic lymphocytic leukemia, CML chronic 
myeloid leukemia, GIST gastrointestinal stromal tumors, HCC hepatocellular carcinoma, IL-6 interleukin-6, NHL non-Hodgkin lymphoma, NSCLC non-small-cell 
lung cancer, MCL mantle cell lymphoma; MDS myelodysplastic syndrome, MM multiple myeloma, MPN myeloproliferative neoplasm, PMF primary myelofibrosis, 
VEGF vascular endothelial growth factor, PDGFR platelet-derived growth factor receptor
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rose after demonstration of its antiangiogenic activ-
ity in a rabbit model of corneal neovascularization that 
was induced in response to bFGF [32]. Thalidomide and 
the newer IMiDs (e.g., lenalidomide) have been shown 
to significantly decrease the expression of the proan-
giogenic factors VEGF and interleukin-6 in multiple 
myeloma [33]. The newer IMiDs were found to be two 
to three times more potent compared with thalidomide 
concerning antiangiogenic activity in various in vivo 
assays [34]. The antiangiogenic activity of IMiDs has 
been shown to be independent of their immunomodu-
latory effects [35]. In a recent study, the antiangiogenic 
effect of lenalidomide was studied in vitro in bone mar-
row endothelial cells of patients with multiple myeloma 
and in vivo using the chorioallantoic membrane assay. 
Lenalidomide exerted a relevant antiangiogenic effect in 
vivo at 1.75 μmol/L, a dose reached in interstitial fluids 
of patients treated with 25  mg/day. In vitro, lenalido-
mide inhibited angiogenesis and migration of multiple 
myeloma endothelial cells [36].
In a phase II study of 44 PMF patients, the efficacy of 
thalidomide monotherapy was assessed [37]. Of 41 eval-
uable patients receiving treatment for at least 15 days, 17 
(41 %) showed a response. CR (without reversal of bone 
marrow fibrosis) was achieved in four patients (10 %) 
and partial response in four (10 %), and hematological 
improvements of anemia, thrombopenia, and/or spleno-
megaly were observed in nine patients (21 %). In phase II 
studies with lenalidomide monotherapy in patients with 
symptomatic PMF, the overall response rates were 22 % 
for anemia, 33 % for splenomegaly, and 50 % for throm-
bocytopenia [38]. In a combination study of lenalido-
mide with prednisone in 40 PMF patients [39], responses 
were recorded in 12 patients (30 %) and are ongoing in 10 
(25 %), with a median time to response of 12 weeks. Three 
patients (7.5 %) had partial response and nine (22.5 %) 
had clinical improvement lasting a median of 18 months. 
Overall response rates were 30 % for anemia and 42 % 
for splenomegaly. Interestingly, all eight JAK2-V617F-
positive responders also experienced a reduction of the 
baseline mutant allele burden. In a study with pomalido-
mide, a newer IMiD, in patients with MF, 94 patients were 
treated with pomalidomide with or without prednisone. 
Overall anemia response was 27 % and increased to 53 % 
in JAK2V617F-positive patients. Median duration of ane-
mia response was 16 months. Treatment effect on sple-
nomegaly was negligible [40].
JAK1 and JAK2 inhibitors
Ruxolitinib is a potent and selective inhibitor against 
both JAK1 and JAK2. It is the first approved JAK2 inhibi-
tor for the treatment of myelofibrosis. The COMFORT-I 
trial assessed the activity of ruxolitinib at 15 or 20  mg 
orally twice daily in 309 patients with PMF, or with post-
PV or post-ET MF, whereas COMFORT-II trial compared 
the activity of ruxolitinib in 219 patients with PMF or 
post-PV or post-ET MF against the best available ther-
Tyrosine kinase inhibitors
Small TKI that target VEGFR are a further important class 
of antiangiogenic drugs with application to MPN, although 
their efficacy in hematolymphoid neoplasias might be 
attributable to inhibition of a variety of pathways. Small-
molecule inhibitors targeting VEGFRs and other kinases, 
e.g., sorafenib (Nexavar) and sunitinib (Sutent), have 
been approved based on their efficacy in treating renal cell 
and hepatocellular carcinoma [23, 24]. Vatalanib is an oral 
angiogenesis inhibitor that is active against VEGFR and 
platelet-derived growth factor receptor tyrosine kinases, 
thereby offering a novel approach to inhibiting tumor 
growth [25] by interfering with the ATP-binding sites of 
VEGFR. In a phase I dose-escalation study, vatalanib, a 
VEGFR TKI, was administered to 29 PMF patients at doses 
of 500 or 750 mg bid [26]. One patient (3 %) achieved CR 
(complete remission) and five (17 %) achieved clinical 
improvement. Transient potentially vatalanib-related 
toxicities were mild nausea, vomiting, dizziness, fatigue, 
or thrombocytopenia. Cumulatively, this study indicated 
that vatalanib had modest activity in PMF patients.
Anti-VEGF antibodies
The first antiangiogenic agent to be approved in solid 
tumors was bevacizumab (Avastin), a humanized anti-
VEGF monoclonal antibody. Administration of bevaci-
zumab, in combination with cytotoxic chemotherapy, 
conferred benefits to patients with several tumor entities 
like metastatic colorectal cancer, nonsquamous, non-
small-cell lung cancer, and metastatic breast cancer [27, 
28]. In a phase II study, bevacizumab monotherapy was 
tested in patients with symptomatic, relapsed/refrac-
tory PMF. A total of 13 patients were enrolled in the first 
stage of this two-stage trial. Among the 11 patients who 
received therapy, only 3 received more than 4 cycles 
of therapy; none of the patients achieved an objective 
response. Furthermore, significant toxicity, not directly 
related to the vascular or gastrointestinal events typically 
associated with the anti-VEGF monoclonal antibody 
preparation in other disease states, was observed. Lack of 
objective responses coupled with toxicity led to the deci-
sion to terminate the study early. The authors concluded 
that if future studies incorporate bevacizumab in com-
bination therapy for myelofibrosis, more modest doses 
should be considered [29].
Immunomodulatory drugs
Thalidomide was originally introduced as sedative and 
withdrawn in the 1960s due to deleterious side effects. 
Recently, there is increasing evidence for the efficacy of 
thalidomide in cancer therapy. The surprising effects of 
thalidomide have led to the development of a series of 
IMiDs with even higher antiangiogenic potency [30, 31]. 
The interest on thalidomide as an antineoplastic agent 
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apy (BAT). The proportion of patients with at least a 
35 % reduction in spleen volume was detected by either 
magnetic resonance imaging (MRI) or computed tomog-
raphy at 24 (COMFORT-I) or 48 (COMFORT-II) weeks 
of therapy. In COMFORT-I, the reduction in spleen vol-
ume was observed in 41.9 % of patients taking ruxolitinib 
compared with 0.7 % taking placebo; the proportion 
of patients with a reduction of 50 % or more in the total 
symptom score from baseline to week 24 was 45.9 % in 
the ruxolitinib group versus 5.3 % in the placebo group 
[41, 42]. In COMFORT-II, the reduction in spleen volume 
was observed in 28 % of patients on ruxolitinib compared 
with 0 % on BAT after a 48-week follow-up period [41, 
42]. The 3-year follow-up data with ruxolitinib in patients 
with myelofibrosis showed, in the ruxolitinib arm, with 
continued therapy, spleen volume reductions of ≥ 35 % by 
MRI were sustained for at least 144 weeks, with the prob-
ability of 50 %. A total of 45 % of the patients randomized 
to ruxolitinib remained on treatment, and ruxolitinib 
continues to be well tolerated. Anemia and thrombocy-
topenia were the main toxicities, but they were generally 
manageable, improved over time, and rarely led to treat-
ment discontinuation. Additionally, patients random-
ized to ruxolitinib showed longer overall survival than 
those randomized to BAT [43].
Conclusions
Angiogenic and especially VEGF/VEGFR pathways are 
possibly involved in the pathophysiology of MPN. VEGF/
VEGFR interactions can stimulate proliferation, migration, 
and survival of leukemia/lymphoma cells by autocrinous 
and paracrinous loops. Novel agents, targeting VEGF, its 
receptors, and other angiogenic pathways, are in various 
stages of clinical development and investigation in MPN. 
As we know from the treatment of solid tumors, combina-
tion therapies of different antiangiogenic molecules with 
chemotherapy or irradiation increases treatment efficacy. 
However, not all patients treated with antiangiogenic ther-
apies benefit from this kind of therapy, and in most cases, 
the effect is transient. It has to be kept in mind that most of 
these studies used anti-VEGF monotherapy to treat heav-
ily pretreated, refractory, or relapsed patients. The molec-
ular diagnostic gap in JAK2/MPL-unmutated ET/PMF is 
now partially addressed by the recent discovery of CALR 
mutations in the majority of such cases.
Take-home message 
 ● Angiogenesis is possibly involved in the pathophysiol-
ogy of myeloproliferative neoplasms (MPN).
 ● New molecular markers like calreticulin provide addi-
tional diagnostic and prognostic tools in MPN wild-
type for JAK2 and MPL.
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